Clinical Trials Logo

Chronic Lymphocytic Leucemia clinical trials

View clinical trials related to Chronic Lymphocytic Leucemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT02445131 Completed - Clinical trials for Chronic Lymphocytic Leucemia

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Start date: May 28, 2015
Phase: Phase 2
Study type: Interventional

The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients

NCT ID: NCT02401503 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leucemia

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

Start date: May 6, 2015
Phase: Phase 2
Study type: Interventional

The CLL2-BAG-trial is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of a debulking with Bendamustine followed by an induction with GA101 (obinutuzumab) and ABT-199 (venetoclax, GDC-0199) followed by ABT-199 and GA101-maintenance in CLL patients

NCT ID: NCT02345863 Completed - Clinical trials for Chronic Lymphocytic Leucemia

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Start date: January 16, 2015
Phase: Phase 2
Study type: Interventional

A prospective, open-label, multicenter Phase-II trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in CLL patients.

NCT ID: NCT02320383 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leucemia

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Start date: November 2014
Phase: Phase 2
Study type: Interventional

A Prospective, Multicenter, Randomized Phase-Ii Trial Comparing Efficacy And Safety Of Fludarabine + Cyclophosphamide + Ga101 (Fcg) And Bendamustine + Ga101 (Bg) In Patients With Relapsed Or Refractory Cll Followed By Maintenance Therapy With Ga101 For Responding Patients